TRIM24 and dermatomyositis: Fujimoto et al. reported a higher incidence of malignancy in patients affected by dermatomyositis and both anti-TIF1-γ and anti-TIF1-ɑ compared to patients with isolated TIF1-γ antibodies (73 vs 50%, respectively) [33].